Achilles On Getting ‘New Wave’ Immunotherapy From Concept To Clinic In Three Years
Clonal neoantigen immunotherapy developer Achilles Therapeutics tells the Pink Sheet how the regulatory landscape for advanced therapies might not be as tricky as it used to be.